Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Although established from cells taken from a patient with a plasma cell leukemia, this line has been shown to be an EBV-transformed B lymphoblastoid cell line.
The cells are positive for Epstein-Barr nuclear antigen(EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +).
The line has been cured of a previous mycoplasma infection.
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 x 105 viable cells/mL and maintain between 1 x 105 and 1 x 106 cells/mL.
Burk KH, et al. Establishment of a human plasma cell line in vitro. Cancer Res. 38: 2508-2513, 1978. PubMed: 566614
Cote RJ, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80: 2026-2030, 1983. PubMed: 6572959
Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
Edwards PA, et al. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur. J. Immunol. 12: 641-648, 1982. PubMed: 7140810
Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375
Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762
Drewinko B, et al. ARH-77, an established human IgG-producing myeloma cell line. I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer 54: 1883-1892, 1984. PubMed: 6090003
